Artiva Biotherapeutics, Inc. Common Stock
ARTVStock
$9.04+328.90%52W
Market Cap$481.99M
P/E—
Div yield—
Beta6.14
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)103.34%
Price vs S&P 500 (4W)2.25%
VGM Score87.75
Market Capitalization$481.99M
Earnings Surprise History
Q1 26-0.95est. -0.89
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.25
4.25
4.25
4.25
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ARTVArtiva Biotherapeutics, Inc. Common Stock | — | — | A | $9.04 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Artiva Biotherapeutics develops allogeneic NK cell therapies designed to treat hematologic malignancies and solid tumors. The company's lead program, AlloNK, is an off-the-shelf, cryopreserved NK cell therapy engineered to enhance the antibody-dependent cellular cytotoxicity of monoclonal antibodies. Its pipeline also includes CAR-NK cell candidates (AB201 and AB205) supported by both internal and collaborative funding.